Psychiatric News (5/17) reports on a study published in AJP in Advance in which researchers examined “how the cumulative effects of medications with anticholinergic properties (decrease the activity of the neurotransmitter acetylcholine) may contribute to worse cognitive outcomes.” The study’s authors wrote, “Efforts to limit or avoid excessive anticholinergic medication burden–regardless of source–may have a beneficial impact on cognitive outcomes in schizophrenia.” (SOURCE: APA Headlines)